Mitogen-Activated Protein Kinase Kinases

"Mitogen-Activated Protein Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A serine-threonine protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily.

Descriptor ID	D020929
MeSH Number(s)	D08.811.913.696.620.682.700.565 D08.811.913.696.620.682.725.200 D12.644.360.440 D12.776.476.440
Concept/Terms	Mitogen-Activated Protein Kinase Kinases Mitogen-Activated Protein Kinase Kinases Mitogen Activated Protein Kinase Kinases MAPKK MAPKKs MAP Kinase Kinases Kinase Kinases, MAP Kinases, MAP Kinase MAPK Kinases Kinases, MAPK Map Kinase Kinase Kinase Kinase, Map Kinase, Map Kinase MAPK-ERK Kinases MAPK-ERK Kinases Kinases, MAPK-ERK MAPK ERK Kinases MEKs MAP-ERK Kinase Kinase, MAP-ERK MAP ERK Kinase

Below are MeSH descriptors whose meaning is more general than "Mitogen-Activated Protein Kinase Kinases".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Serine-Threonine Kinases [D08.811.913.696.620.682.700]
Mitogen-Activated Protein Kinase Kinases [D08.811.913.696.620.682.700.565]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Mitogen-Activated Protein Kinase Kinases [D08.811.913.696.620.682.725.200]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intracellular Signaling Peptides and Proteins [D12.644.360]
Mitogen-Activated Protein Kinase Kinases [D12.644.360.440]
Proteins [D12.776]
Intracellular Signaling Peptides and Proteins [D12.776.476]
Mitogen-Activated Protein Kinase Kinases [D12.776.476.440]

Below are MeSH descriptors whose meaning is related to "Mitogen-Activated Protein Kinase Kinases".

Below are MeSH descriptors whose meaning is more specific than "Mitogen-Activated Protein Kinase Kinases".

Mitogen-Activated Protein Kinase Kinases
MAP Kinase Kinase 1
MAP Kinase Kinase 2
MAP Kinase Kinase 3
MAP Kinase Kinase 4
MAP Kinase Kinase 5
MAP Kinase Kinase 6
MAP Kinase Kinase 7

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Mitogen-Activated Protein Kinase Kinases" by people in this website by year, and whether "Mitogen-Activated Protein Kinase Kinases" was a major or minor topic of these publications.

Bar chart showing 45 publications over 23 distinct years, with a maximum of 7 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1998	2	0	2
1999	0	2	2
2000	1	0	1
2001	1	0	1
2002	2	4	6
2003	3	4	7
2004	2	3	5
2005	1	0	1
2007	0	3	3
2008	1	0	1
2009	0	1	1
2010	1	0	1
2011	0	1	1
2012	1	2	3
2014	0	1	1
2015	1	0	1
2016	0	1	1
2018	0	1	1
2019	0	1	1
2021	0	1	1
2023	0	2	2
2024	0	1	1

Below are the most recent publications written about "Mitogen-Activated Protein Kinase Kinases" by people in Profiles.

Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I, Steven N, Lorigan P, Plummer R, Patel P, Psarelli E, Olsson-Brown A, Shaw H, Leyvraz S, Handley L, Rawcliffe C, Nathan P. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. Eur J Cancer. 2024 May; 202:114009.

View in: PubMed
Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis. Clin Cancer Res. 2023 12 01; 29(23):4930-4940.

View in: PubMed
Kim DY, Swetter SM, Huhmann L, Dizon MP, Ferguson JM, Osborne TF, Spence AC, Ziad A, Fillmore N, Hartman RI. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma. J Am Acad Dermatol. 2024 03; 90(3):620-623.

View in: PubMed
Hemond CC, Bakshi R, Tauhid S, Sarrosa R, Ryan M, Kamath V, Thomas J, Edwards KR. Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211033047.

View in: PubMed
Winters MJ, Pryciak PM. MAPK modulation of yeast pheromone signaling output and the role of phosphorylation sites in the scaffold protein Ste5. Mol Biol Cell. 2019 04 01; 30(8):1037-1049.

View in: PubMed
De Nardo D, Balka KR, Cardona Gloria Y, Rao VR, Latz E, Masters SL. Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling. J Biol Chem. 2018 09 28; 293(39):15195-15207.

View in: PubMed
Thompson IR, Ciccone NA, Zhou Q, Xu S, Khogeer A, Carroll RS, Kaiser UB. GnRH Pulse Frequency Control of Fshb Gene Expression Is Mediated via ERK1/2 Regulation of ICER. Mol Endocrinol. 2016 Mar; 30(3):348-60.

View in: PubMed
Zou J, Wang R, Li R, Kong Y, Wang J, Ning X, Zhang L, Wang S, Hu X, Bao Z. The genome-wide identification of mitogen-activated protein kinase kinase (MKK) genes in Yesso scallop Patinopecten yessoensis and their expression responses to bacteria challenges. Fish Shellfish Immunol. 2015 Aug; 45(2):901-11.

View in: PubMed
Tang Z, Dai S, He Y, Doty RA, Shultz LD, Sampson SB, Dai C. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1. Cell. 2015 Feb 12; 160(4):729-744.

View in: PubMed
Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014 Sep 03; 6(252):252ra121.

View in: PubMed

People

Explore

Similar Concepts

Top Journals